In conclusion, as a proliferation index, the expression levels of Ki-67 are correlated with KRAS- or EGFR mutations and the efficacy of first-line chemotherapy or EGFR-TKIs therapy in advanced or postoperative-recurrent NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.